Immunotherapy-associated autoimmune hemolytic anemia

Immunotherapy-associated autoimmune hemolytic anemia

BACKGROUND Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) pathway are the prototypic checkpoint targets for immunotherapy. When combined, CTLA-4 and PD-1 checkpoint inhib...

Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia

Warm autoimmune hemolytic anemia (WAIHA) is one of four clinical types of autoimmune hemolytic anemia (AIHA), with the characteristics of autoantibodies maximally active at body temperature. It produces a variable anemia-sometimes mild and sometimes severe. With respect to the absence or presence of an underlying condition, WAIHA is either idiopathic (primary) or secondary, which determines the...

Multiple myeloma associated with autoimmune hemolytic anemia.

A rare case of multiple myeloma associated with severe Coombs-positive hemolytic anemia is described. A 60-year-old woman was hospitalized for acute hemolysis due to an IgG warm autoantibody with pan-agglutinin specificity. Serum and urine electrophoresis revealed the presence of a monoclonal IgGk protein and a BJk protein, respectively. Bone marrow aspirates showed diffuse infiltration with pl...

Monophasic CIDP Associated with Autoimmune Hemolytic Anemia.

Unlike other autoimmune polyneuropathies, the linkage between chronic inflammatory demyelinating polyneuropathy (CIDP) and other immune mediated disorders is weak. We report a patient who developed monophasic and parallel courses of autoimmune hemolytic anemia (AIHA) and chronic demyelinating polyneuropathy. Both resolved in tandem with corticosteroid therapy. Distinct from Guillain-Barre Syndr...

Autoimmune Hemolytic Anemia